Johnson Matthey Medical Device Components

Johnson Matthey Medical Device Components

Johnson Matthey traces its origins to 1817, when Percival Norton Johnson assayed gold in a small London shop. The firm evolved from precious metals refining into a FTSE 100 speciality chemicals and sustainable technologies group. Its Medical Device Components division, now a core strategic pillar under CEO Liam Condon's simplification plan, supplies wire, micro-tubes, and sub-assemblies made from noble metals and nitinol to the interventional device industry. The parent company has publicly outlined a strategy to divest non-core assets and concentrate on businesses like this one, where it holds deep materials science intellectual property. The division's deployment centers on manufacturing high-tolerance components — guidewires, catheter shafts, stent frames, and embolic coils — for Class III medical devices. Primary materials include platinum-tungsten, platinum-iridium, and nitinol alloys drawn to micron-level tolerances. Johnson Matthey's Medical Device Components business serves the structural heart, electrophysiology, and neurovascular markets, with a geographic footprint spanning manufacturing sites in the United States, Mexico, and Europe. Key device customers are undisclosed due to contractual confidentiality, but public record consistently places its components at the center of major OEM supply chains for ischemic stroke treatment and transcatheter valve repair. The unit operates within Johnson Matthey's broader group, which employs over 12,000 people globally. Condon has not broken out standalone revenue for Medical Device Components since taking over the reorganization in 2022, though the division falls under the Catalyst Technologies reporting segment. Adjacent to the medical business, Johnson Matthey maintains a substantial hydrogen technologies and fuel cell components platform, sharing materials science R&D but serving an entirely separate end market. In May 2024, Condon announced the sale of the group's Medical Device Components business to Montagu Private Equity for an enterprise value of $700 million (per Reuters, May 2024), signaling a full strategic pivot away from medtech. The business was never structured as an independent operator — it functioned as a vertically integrated materials-to-components engine inside a public company balance sheet. That structure gave it capital equipment scale and metallurgical refinery access that standalone contract manufacturers cannot replicate. The Montagu carve-out, expected to close in late 2024, will test whether the division's value derived from its balance sheet integration or its customer-locked position as a sole-source supplier on approved vendor lists requiring years to revalidate.